切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2023, Vol. 17 ›› Issue (12) : 1209 -1211. doi: 10.3877/cma.j.issn.1674-0785.2023.12.001

所属专题: 临床药学

述评

自身免疫性疾病的药物治疗
高君伟, 刘皋林()   
  1. 200080 上海,上海交通大学医学院附属第一人民医院临床药学科
  • 收稿日期:2023-08-15 出版日期:2023-12-15
  • 通信作者: 刘皋林

Drug therapies for autoimmune diseases

Junwei Gao, Gaolin Liu()   

  1. Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 20080, China
  • Received:2023-08-15 Published:2023-12-15
  • Corresponding author: Gaolin Liu
引用本文:

高君伟, 刘皋林. 自身免疫性疾病的药物治疗[J/OL]. 中华临床医师杂志(电子版), 2023, 17(12): 1209-1211.

Junwei Gao, Gaolin Liu. Drug therapies for autoimmune diseases[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(12): 1209-1211.

自身免疫性疾病困扰着全球约10%的人群,因发病机制复杂,一直是药物研发领域的热点之一。目前自身免疫性疾病的治疗主要包括激素、免疫抑制剂、免疫调节剂、抗炎药物等传统的合成抗风湿药(DMARDs),大分子单克隆抗体或其衍生物如英夫利昔单抗、托珠单抗等生物DMARDs,JAK抑制剂如托法替尼、巴瑞特尼等等小分子靶向DMARDs。这类疾病的治疗通常需要数月甚至数年,药物不良反应的监测非常重要,不论是传统的DMARDs还是新型的生物或靶向DMARDs。天然类药物由于靶点广泛、安全性好,以及在免疫调节方面的潜在作用,如姜黄素、白藜芦醇、火把花根等制剂,在临床前或临床研究中显示了其在自身免疫性疾病治疗中的良好开发前景。

Autoimmune diseases, affecting about 10% of the world's population, have been one of the hotspots in the field of drug research because of their complex pathogenesis. The treatments for autoimmune diseases mainly include traditional synthetic disease-modifying antirheumatic drugs (DMARDs) such as glucocorticoids, immunosuppressants, immunomodulators, and anti-inflammatory drugs, macromolecular monoclonal antibodies or their derivatives such as Infliximab and Tolizumab, and small molecule targeted DMARDs such as JAK inhibitors Tofacitinib and Baritinib. The treatment of these diseases usually takes months or even years. Thus, adverse drug reaction monitoring is very important, regardless of whether they are traditional DMARDs or new biological DMARDs. For their wide range of targets, good safety, and potential role in immune regulation, natural drugs such as curcumin, resveratrol, and colquhounia root have shown good potential in the treatment of autoimmune diseases in preclinical or clinical studies.

1
Scherlinger M, Mertz P, Sagez F, et al. Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014 [J]. Autoimmun Rev, 2020,19(6):102531.
2
Cao F, He YS, Wang Y, et al. Global burden and cross-country inequalities in autoimmune diseases from 1990 to 2019 [J]. Autoimmun Rev, 2023,22(6):103326.
3
Jayatilleke A. Immunosuppression in rheumatologic and auto-immune disease [J]. Handb Exp Pharmacol, 2022,272:181-208.
4
Salomon BL. Insights into the biology and therapeutic implications of TNF and regulatory T cells [J]. Nat Rev Rheumatol, 2021,17(8):487-504.
5
Geddes L, Iversen J, Wand H, et al. Sex discrepancies in the protective effect of opioid agonist therapy on incident hepatitis C infection [J]. Clin Infect Dis, 2020,70(1):123-131.
6
Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus [J]. N Engl J Med, 2020,382(3):211-221.
7
Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors [J]. N Engl J Med, 2017,377(16):1525-1536.
8
Wells AF, Edwards CJ, Kivitz AJ, et al. Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial [J]. Rheumatology (Oxford), 2018,57(7):1253-1263.
9
Khojah HM, Ahmed S, Abdel-Rahman MS, et al. Resveratrol as an effective adjuvant therapy in the management of rheumatoid arthritis: a clinical study [J]. Clin Rheumatol, 2018,37(8):2035-2042.
10
Liu W, Zhang Y, Zhu W, et al. Sinomenine inhibits the progression of rheumatoid arthritis by regulating the secretion of inflammatory cytokines and monocyte/macrophage subsets [J]. Front Immunol, 2018,9:2228.
11
Hang Y, Qin X, Ren T, et al. Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial [J]. Lipids Health Dis, 2018,17(1):146.
12
王露, 刘泽有, 张方. 火把花根片联合来氟米特治疗系统性红斑狼疮的临床效果观察 [J]. 临床医学工程,2023,30(1):49-50.
13
李健, 赵雪峰, 桂凤娇,等. 火把花根片联合来氟米特治疗类风湿性关节炎的临床研究 [J]. 现代药物与临床,2022,37(10):2333-2338.
14
郭敏, 杜跃亮. 火把花根片联合氯沙坦钾片治疗IgA肾病的效果及作用机制 [J]. 实用中西医结合临床,2023,23(7):21-23,40.
[1] 中华医学会骨科学分会关节外科学组, 广东省医学会骨质疏松和骨矿盐疾病分会, 广东省佛山市顺德区第三人民医院. 中国髋部脆性骨折术后抗骨质疏松药物临床干预指南(2023年版)[J/OL]. 中华关节外科杂志(电子版), 2023, 17(06): 751-764.
[2] 江泽莹, 王安婷, 王姣丽, 陈慈, 周秋玲, 黄燕娟, 周芳, 薛琰, 周剑烽, 谭文勇, 杜美芳. 多种植物油组分预防肿瘤放化疗相关毒性反应的效果分析[J/OL]. 中华损伤与修复杂志(电子版), 2023, 18(06): 523-527.
[3] 张静, 刘畅, 华成舸. 妊娠期患者口腔诊疗进展[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(05): 340-344.
[4] 严华悦, 刘子祥, 周少波. 磷酸烯醇式丙酮酸羧激酶-1在恶性肿瘤中的研究进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 452-456.
[5] 屈少华, 胡晔东, 赵修浩, 李文娜, 向鹏程, 肖子添, 马启明, 韩俊毅. 伴有无效食管动力的胃食管反流病用药和手术治疗的效果对比[J/OL]. 中华普通外科学文献(电子版), 2024, 18(01): 23-28.
[6] 赵燕, 王昱昊, 王娟, 杨建军. 胃肠间质瘤的诊疗进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(01): 66-70.
[7] 肖伍豪, 刘抗寒. 晚期慢性肾脏病患者骨质疏松症的治疗研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(02): 92-96.
[8] 潘冬生, 梁国标. 颅脑创伤治疗的最新进展与未来趋势[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(04): 193-197.
[9] 汤畅通, 王永楠, 王诗筌. 颅脑外伤后阵发性交感神经兴奋患者的药物治疗效果分析[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(04): 233-237.
[10] 吴天宇, 刘子璇, 杨浦鑫, 贾思明, 丁凯, 程晓东, 李泳龙, 陈伟, 吕红芝, 张奇. 腰椎间盘突出症保守治疗进展[J/OL]. 中华老年骨科与康复电子杂志, 2024, 10(06): 379-384.
[11] 李瑞华, 周炜, 刘洋. 腹主动脉瘤的药物治疗进展:一项系统综述和网状荟萃分析[J/OL]. 中华临床医师杂志(电子版), 2023, 17(12): 1277-1284.
[12] 陈秋怡, 林熙, 刘珍银. 淋巴管畸形分子机制的研究进展[J/OL]. 中华介入放射学电子杂志, 2024, 12(04): 374-379.
[13] 胡瑞芳, 樊丽娟. 食管鳞状上皮内瘤变诊断的生物标志物研究进展及其非内镜治疗现状[J/OL]. 中华诊断学电子杂志, 2024, 12(04): 281-286.
[14] 张成惠, 闫中瑞, 盛志强, 袁嫣然. 脑肌酸缺乏症诊断与治疗研究进展[J/OL]. 中华诊断学电子杂志, 2024, 12(04): 270-275.
[15] 赵晓晓, 邱嘉婷, 张懿姝, 张蓉, 张棚, 刘晓蕾. 丁苯酞在各类型认知障碍治疗中的应用研究进展[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(01): 19-26.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?